Frankfurt
09.01.26 | 15:29
3,900 Euro
-2,99 % -0,120
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | UBS startet Coverage für Inventiva mit Kaufempfehlung und 12-Dollar-Kursziel | 7 | Investing.com Deutsch | ||
| Mi | UBS assumes coverage on Inventiva stock with Buy rating, $12 target | 3 | Investing.com | ||
| 17.12.25 | INVENTIVA: Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference | 338 | GlobeNewswire (Europe) | Daix) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH")... ► Artikel lesen | |
| 28.11.25 | Inventiva S.A. - 6-K, Report of foreign issuer | 13 | SEC Filings | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 28.11.25 | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of November 27, 2025 | 609 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 28, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 24.11.25 | INVENTIVA: Information relating to the stabilization activities carried out in the context of its recent offering | 348 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 24, 2025 - Publication of information relating to the stabilization activities carried out in the context of the recent public offering... ► Artikel lesen | |
| 24.11.25 | Inventiva S.A. reports nine-months results | 4 | Seeking Alpha | ||
| 21.11.25 | Inventiva S.A reports 9M results | 1 | Seeking Alpha | ||
| 21.11.25 | INVENTIVA: Inventiva reports 2025 Third Quarter Financial Information | 801 | GlobeNewswire (Europe) | Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the... ► Artikel lesen | |
| 18.11.25 | Inventiva stock price target lowered to $11 at Guggenheim on financing | 5 | Investing.com | ||
| 17.11.25 | INVENTIVA: Inventiva announces full exercise of Underwriters' Option, bringing proceeds of Offering to approximately $172.5M | 406 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 17, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 13.11.25 | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.11.25 | Inventiva Prices Of Upsized Public Offering Of About $150 Mln ADS | 1 | RTTNews | ||
| 13.11.25 | Inventiva resumes trading on Euronext Paris after ADS offering halt | 1 | Investing.com | ||
| 13.11.25 | Inventiva: Handel an Euronext Paris nach Aussetzung wegen ADS-Angebots wieder aufgenommen | 3 | Investing.com Deutsch | ||
| 13.11.25 | INVENTIVA: Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares | 357 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 13, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 12.11.25 | INVENTIVA: Inventiva announces launch of public offering | 899 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 12, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 06.11.25 | INVENTIVA: Combined General Meeting of November 27, 2025 - Availability of the preparatory documents | 389 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 6, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 06.11.25 | INVENTIVA: Statement of total voting rights and shares forming the company's share capital as October 20, 2025 | 309 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com
Date Number of Shares Outstanding
... ► Artikel lesen | |
| 06.11.25 | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 13,830 | -5,63 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 | - Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 73,25 | +0,85 % | U.S. Court Blocks Edwards Lifesciences' Acquisition Of JenaValve; Company Revises 2026 Adj. EPS View | WASHINGTON (dpa-AFX) - Edwards Lifesciences (EW) announced that the U.S. District Court for the District of Columbia has granted the Federal Trade Commission's (FTC) motion for an injunction... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,520 | +2,01 % | Organigram Global Inc: Organigram increases Phylos loan by $3-million (U.S.) | ||
| ASSEMBLY BIOSCIENCES | 27,300 | +1,11 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,320 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Rosie's Burgers Announces the Grand Opening of Its Newest Location in Calgary's Marda Loop Neighbourhood | Toronto, Ontario--(Newsfile Corp. - January 9, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 146,00 | +1,53 % | Morgan Stanley downgrades Axsome stock after 23% rally, raises price target | ||
| COMPASS PATHWAYS | 6,150 | -6,11 % | Compass Pathfinder Limited: Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD | FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues... ► Artikel lesen | |
| ALTIMMUNE | 3,428 | -2,22 % | Altimmune, Inc: Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH | GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,615 | -1,81 % | Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program | One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 140,80 | +2,36 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer | Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions
... ► Artikel lesen | |
| DAIICHI SANKYO | 19,550 | +0,90 % | Organon & Co.: Organon schließt Vermarktungsvereinbarung für Nilemdo von Daiichi Sankyo in Frankreich, Dänemark, Island, Schweden, Finnland und Norwegen | Die Vereinbarung baut auf dem Portfolio von Organon im Bereich Herz-Kreislauf-Erkrankungen auf und nutzt das Fachwissen des Unternehmens, um Patienten mit Dyslipidämie, insbesondere Patienten mit... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 2,975 | -10,53 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| XORTX THERAPEUTICS | 0,486 | -2,61 % | XORTX Therapeutics Inc.: XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update | CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City | DENVER, CO / ACCESS Newswire / December 18, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 37,000 | -3,14 % | Rigel Pharmaceuticals: Geht es 2026 noch höher? | Die Aktie von Rigel Pharmaceuticals hatten wir sharedealsPlus-Nutzern erstmals im Jahr 2022 ans Herz gelegt. Der Kurs konnte seitdem über 400% zulegen und auch unser September-Update mit Verweis auf... ► Artikel lesen |
Das Unternehmen INVENTIVA SA ADR kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,120 (-2,99 %) liegt der Kurs bei 3,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.